 The primary objective of the study is to evaluate the evolution of walking capacity as measured by the timed 100-meter walk test T100T, timed 25-foot walk test T25FW, maximum walking distance MWD, and Expanded Disability Status Scale EDSS during the first year of therapy with natalizumab. The secondary objectives of this study are as follows: 